Ultragenyx Pharmaceutical
RARE
172 hedge funds and large institutions have $3.99B invested in Ultragenyx Pharmaceutical in 2015 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 74 increasing their positions, 51 reducing their positions, and 15 closing their positions.
67% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 15
45% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 51
17% more capital invested
Capital invested by funds: $3.41B → $3.99B (+$585M)
6% more funds holding
Funds holding: 162 → 172 (+10)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
20% less call options, than puts
Call options by funds: $10.2M | Put options by funds: $12.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$42.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.5M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$22M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$19.5M |
| 5 |
State Street
Boston,
Massachusetts
|
+$12.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
-$43.6M |
| 2 |
Millennium Management
New York
|
-$34.7M |
| 3 |
Two Sigma Investments
New York
|
-$14.5M |
| 4 |
Goldman Sachs
New York
|
-$14.2M |
| 5 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$14.1M |
RARE Hedge Fund Activity: Q4 2015 in Review
172 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q4 2015, worth a combined $3.99B — up 17% from $3.41B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new RARE positions and 15 closed out — a net gain of 10 holders — while 74 added to existing stakes and 51 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $42.1M. The largest seller was TPG Group Holdings (SBS) Advisors, exiting entirely with an estimated $43.6M sold.
- 172 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q4 2015, up from 162 in Q3 2015.
- Funds reported $3.99B of Ultragenyx Pharmaceutical stock for Q4 2015, up 17% quarter-over-quarter.
- 25 funds opened new Ultragenyx Pharmaceutical positions in Q4 2015 and 15 closed out, a net change of +10 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q4 2015 was Wellington Management Group, an estimated $42.1M added.
- The largest Ultragenyx Pharmaceutical seller in Q4 2015 was TPG Group Holdings (SBS) Advisors, an estimated $43.6M sold.
Based on aggregated 13F filings for Q4 2015.